Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 3/20 | 0.38 |
| ▸ | FNTB | P49356 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9808075 | 1.00 | GABRR1 (0.43) | GABRR1CYP1A2ACE2BLMFNTA | |
| SCHEMBL26624652 | 0.89 | LTA4H (0.44) | GABRR1CYP1A2ACE2BLMFNTA | |
| SCHEMBL13384296 | 0.85 | CYP1A2 (0.45) | GABRR1CYP1A2ACE2BLMFNTA | |
| SCHEMBL18403957 | 0.82 | ALOX15 (0.35) | FNTAFNTBKDM1AALDH1A1ALOX15 | |
| SCHEMBL13384151 | 0.82 | FNTA (0.49) | CYP1A2ACE2FNTAFNTBKDM1A | |
| SCHEMBL5369538 | 0.81 | ALDH1A1 (0.51) | GABRR1CYP1A2BLMFNTAFNTB | |
| SCHEMBL13383956 | 0.81 | GABRR1 (0.41) | GABRR1CYP1A2ACE2BLMFNTA | |
| SCHEMBL13384294 | 0.80 | KDM1A (0.46) | GABRR1CYP1A2ACE2BLMFNTA | |
| SCHEMBL10427314 | 0.79 | ALOX15 (0.38) | KDM1AALDH1A1ALOX15 | |
| SCHEMBL9808113 | 0.79 | ALOX15 (0.38) | KDM1AALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0284363-B1 | 2, 6-DIMETHYL OCTYLFORMATE AND AN ATTRACTANT OF TRIBOLIUM CASTANEUM HERBST | Japan Tobacco Inc. (JP) | 1991-05-22 | — | — | EP | claimed |
| US-20240408180-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4412587-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023059846-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022271537-A1 | COMPOSITIONS AND METHODS RELATING TO INJECTABLE MICROEMULSIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220257767-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3946261-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939273-A | Ionic liquids for drug delivery | 哈佛大学校长及研究员协会 | 2022-01-14 | — | — | CN | disclosed |
| EP-3165925-B1 | METHODS FOR THE DIAGNOSIS OF COLORECTAL CANCER | MED LIFE DISCOVERIES LP (CA) | 2021-09-08 | — | — | EP | disclosed |
| US-20210041444-A1 | METHODS FOR DIAGNOSING A COLORECTAL CANCER (CRC) HEALTH STATE OR CHANGE IN CRC HEALTH STATE, OR FOR DIAGNOSING RISK OF DEVELOPING CRC OR THE PRESENCE OF CRC IN A SUBJECT | PHENOMENOME DISCOVERIES INC. (CA) | 2021-02-11 | — | — | US | disclosed |
| US-20160377622-A1 | METHODS FOR DIAGNOSING A COLORECTAL CANCER (CRC) HEALTH STATE OR CHANGE IN CRC HEALTH STATE, OR FOR DIAGNOSING RISK OF DEVELOPING CRC OR THE PRESENCE OF CRC IN A SUBJECT | MED-LIFE DISCOVERIES LP (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160377623-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20080255764-A1 | Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer by the Measurement of Vitamin E-Related Metabolites | PHENOMENOME DISCOVERIES INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255764-A1 | Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer by the Measurement of Vitamin E-Related Metabolites | PHENOMENOME DISCOVERIES INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008092280-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007030928-A2 | METHOD FOR THE DIAGNOSIS OF COLORECTAL CANCER AND OVARIAN CANCER BY THE MEASUREMENT OF VITAMIN E-RELATED METABOLITES | PHENOMENOME DISCOVERIES INC. (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257767-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | GABRR1 2691/4885CYP1A2 1936/4885ACE2 1825/4885 |
| US-20240408180-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | GABRR1 2691/4885CYP1A2 1936/4885ACE2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.